Look back at pharma news in the week to January 24, 2020
By Barbara Obstoj-Cardwell. Editor
Last week’s regulatory news included European approval for Swiss pharma giant Novartis’ Mayzent, its potential blockbuster for the treatment of a particular form of multiple sclerosis. Important clinical trial results featured big, with China’s BeiGene reporting positive new data on its lung cancer candidate tislelizumab and Swiss giant Roche releasing positive results from the FIREFISH study of its spinal muscular atrophy agent risdiplam. Meantime, French drugmaker Ipsen on Friday said it was pausing dosing of patients in a Phase III study of palovarotene for a rare bone disease.
Mayzent approval in EU gives new treatment option for SPMS patients
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze